FDA approves antidepressant nasal spray

Ketamine-derived nasal spray treating Phoenix patients with severe depression
A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t working, but it’s not without risk.
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray,
A Nasal Spray For Depression? FDA Gives Its Approval
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder (MDD) who have not responded adequately to at least two oral antidepressants.
What to Know About the New Nasal Spray for Tough Depression
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Colorado clinic looking to help patients with ketamine-assisted psychotherapy
The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a ...
News & Record11h
FDA approves new painkiller that shows promise and challenges of opioid alternatives
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.
Muscatine Journal21h
National advocacy group condemns racially motivated vandalism in Muscatine
The Council on American-Islamic Relations, the nation’s largest Muslim civil rights and advocacy organization, on Wednesday ...
Bird flu isn't an immediate health threat in New York, but preparations have begun
As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...
PharmiWeb1d
Global Cough Suppressant Market Set for Remarkable Growth, Projected to Reach USD 50,948.51 Million by 2034
Cough Suppressant MarketThe global cough suppressant market is on track for significant expansion, with projections indicating a remarkable surge to a valuation of USD 27,141.6 million by 2024. This ...
Muscatine Journal22h
Court documents provide more details on Muscatine vandalism, alleged hate crimes
Court documents show more details about what investigators believe happened in a string of vandalism over the weekend and why some of the incidents are charged as hate crimes.
pharmaphorum1d
J&J finally decides to dismantle its diversified business model
After decades of a diversified healthcare business model, Johnson & Johnson has announced it plans to split off its consumer health division from its pharma and medical device operations.